CR Sanjiu: CHINARES PHARMA's pediatric tranquilizer and brain supplement granules have received implied approval for clinical trials

AASTOCKS
2025.11.19 04:25

China Resources Pharmaceutical (03320.HK) announced that its subsidiary China Resources Sanjiu's pediatric calming and brain-nourishing granules have obtained implied approval for clinical trials.

This product was jointly developed by China Resources Sanjiu, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen Institute for Drug Inspection and Research, and Shenzhen Traditional Chinese Medicine Manufacturing Innovation Center. It is classified as a new drug of Type 1.1 in traditional Chinese medicine, intended for children with tic disorders due to spleen deficiency and phlegm accumulation, as well as wind-phlegm disturbance. The company expects that obtaining this implied approval for clinical trials will help further enrich its product line and enhance the market competitiveness of its products

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.